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LETTERS TO THE EDITOR
Sir: Many thanks for asking me to comment on the
Dutch consensus document on `Diagnosis and
Treatment of Soft Tissue Tumours’.
The Dutch consensus document on soft tissue
sarcoma (STS) is well done, comprehensible and
apart from minor remarks it could be basically
accepted as a standard.
Nevertheless, the document gives the impression
that agreement exists among specialists in the treat-
ment of STS, and that by simply following these
guidelines, everyone is allowed to treat these lesions.
In practice this is far from true.
In our major Italian cancer centre, and it happens
in many other European institutions, 60% of STS
are seen for rescue treatment after inadequate thera-
pies performed elsewhere. After important progress
in surgical culture and procedures, the likelihood of
achieving a good local control improved, but only in
major institutions.
Results of treatment remain very poor. Surgeons
and radiotherapists insist on stressing their import-
ant role while up to 50% of patients with high-grade
tumours die from metastatic disease waiting for a
missing effective medical treatment. In these cir-
cumstances nothing up to now can be standardized
or imposed.
Surgery is also not optimal even where skill and
facilities are best, but the overall survival for
metastatic spread discourages us from more heavy,
mutilating or dangerous procedures. The document
discusses the possible dangerous impact of the unex-
pected ® nding of sarcoma, typically after minor
operations performed in non-oncological depart-
ments. Despite expectations, these patients have, in
our series, a better prognosis (data reported at the
ECCO Conference, Hamburg 1997). This fact is
probably due to a favourable selection of patients
presenting with small super® cial lesions with a slow
growing pattern.
Radiotherapy (RT) is accepted as a necessary
procedure complementary to surgery, but it is com-
mon experience that its effect is proportional to the
quantity of tumour tissue left behind; the treatment
is acceptable if only a microscopic residual is left
after an adequate macroscopic complete resection.
It is ineffective if macroscopic residual tumour is
left, even if minimal. It should be stressed, and it is
not clear in the document, that RT is not a remedy
for incomplete or improvable surgery. Again the
timing of RT is not yet standardized. Many centres
have a satisfactory experience with pre-operative
RT, and in our Institute we are performing a new
protocol with pre-operative RT for retroperitoneal
tumours.
Chemotherapy is a most confused topic. Reading
the literature, adjuvant chemotherapy is not indi-
cated outside clinical trials. The meta-analysis stim-
ulates ethical questions and in the near future other
investigators will probably state that adjuvant
chemotherapy is mandatory in selected cases.
A minor remark is that the term of `compart-
ment’, so frequently adopted since the early 1980s,
is now obsolete. In fact the only useful compartment
that determines the quality of surgery is the muscu-
lar fascia. The de® nition of intramuscular or extra-
muscular lesion should be preferred.
In conclusion sarcomas are rare, the data con-
fused and physicians should not have the privilege to
treat patients by their own feeling. It is more ethical
for any eligible patient to be entered into a clinical
trial, and that for any simple or complicated case of
STS, or where it is suspected, the physician not
familiar with this disease should contact a speci® c
centre.
A. AZZARELLI
Istituto Nazionale Tumori
Milano, Italy
Sir: Many thanks for asking me to comment on the
Dutch nationwide accepted consensus document on
`Diagnosis and Treatment of Soft Tissue Tumours’.
There is no doubt that the mechanism by which
this consensus document was drawn up has in itself
been very therapeutic. It appears to have been dem-
ocratically derived after a total of nine meetings and
clearly much thought and effort has gone into its
production.
It is a very prescriptive document, de® ning what
should be done in virtually every circumstance
drawing on standard principles of sarcoma care. I
have no doubt that the clinicians who attended the
meetings and who were involved in the production
of these guidelines were all better informed and
better equipped to deal with the challenges posed by
soft tissue sarcomas at the completion of the exer-
cise.
But there are three problems posed by documents
such as this:
1. The guidelines are very precise and allow for
little latitude. Non-adherence to these
guidelines may now be unacceptableÐ both
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clinically and medico legally. Any aberration
from the de® ned pathway may lay that clini-
cian open to claims of an unacceptable or
improper standard of care for that patient.
This may be the case but equally it does not
allow for latitude of innovation, particularly
for the experienced clinician. For the
occasional surgeon, however, these guideli-
nes represent a minimum standard of care
from which he or she varies at his/her peril.
2. These guidelines make turgid reading. How
many clinicians who were not actively
involved in drawing up the original docu-
ment will have read them or even be aware
of them. How many will go and look it up
when and if they get a patient with a soft
tissue sarcoma? For guidelines to be effec-
tive there needs to be a national consensus
of not only how the patient should be
treated but also by whom the patient should
be treated. Should all patients be treated at
a national centre or is there still room for the
`occasional’ surgeon in this ® eld of
oncology. What are the outcomes, does it
matter?Ð I believe that these are still ques-
tions without complete answers.
3. Any document such as this must have an
acknowledged time limit on it such that the
guidelines are reviewed and modi® ed appro-
priately in light of changing ® ndings and
fashions.
How might guidelines such as this be used in the
United Kingdom?
It is an unfortunate fact that in the United King-
dom soft tissue sarcomas continue to be managed
by a variety of surgeons using a whole host of
treatments many of which could not be considered
optimal in light of current knowledge. There is
acceptance that treatment and outcomes tend to be
better if patients are treated in specialist centres for
all forms of cancer but the data con® rming this is
simply not available for soft tissue sarcomas.
Introduction of a document such as this would
help to standardize treatment in the bigger centres
(where treatment will already follow accepted guide-
lines) but will probably not in¯ uence in the slightest
the occasional surgeon who is unlikely to read let
alone acknowledge a document such as this. He will
rightly insist that there are no data showing that
treatment in a specialist centre is better for the
individual. Until this is forthcoming I ® rmly believe
that the most that can be done is to set a minimum
standard of care and to widely circulate this in a
brief and succinct document (see Table 1).
National guidelines should indeed be reached by
consensus but should ideally follow the recognition
of the strengths and weaknesses of a country’s cur-
rent outcomes in an attempt to improve these.
R. J. GRIMER
Birmingham Orthopaedic Oncology
Birmingham, UK.Letters to the Editor 195
Table 1. Document describing minimum standard of care in treatment of soft tissue sarcomas
MANAGEMENT GUIDELINES FOR BONE AND SOFT TISSUE SARCOMAS.
Introduction
Bone and soft tissue sarcomas are a rare and heterogeneous group of tumours. Many clinicians will never see a case during
their professional career. Their recognition is important however, because timely investigation and treatment can result in
cure. Their management requires close collaboration between designated specialists in a multidisciplinary team and early
referral to such a regional or supra-regional service will lead to the best clinical and cost effective care.
There guidelines have been produced in line with current accepted practice not only in this country but within Europe and
the United States. They stem from consensus conferences in these countries and from published guidelines which are
circulated to all interested parties in these countries. There guidelines will be submitted for agreement to the Royal College
of Surgeons, The British Orthopaedic Association, The Medical Research Council.
Presentation
Primary bone tumours can occur at any age. Whereas oteosarcoma and Ewing’s sarcoma have their peak incidence in
adolescence and early adulthood, chondrosarcoma and osteosarcomas secondary to radiation damage and Paget’s disease
increase in frequency with age. Pain is the commonest presenting symptoms in patients with primary bone tumours.
Unfortunately,this is a common complaint after minor trauma and sporting injuries, and a high index of suspicion is required.
Features suggestive of bony malignancy are:
· night pain
· non-mechanical pain (ie. continuous pain not aggravated by exercise)
· swelling that is not associated with a joint
The changes seen on plain radiographs can be subtle, such as periosteal reaction, bone destruction, new bone formation
(calci® cation) and soft tissue swelling. These ® ndings are not speci® c of a bone tumour but are suggestive and always warrant
further investigation.
Soft tissue sarcomas increase in frequency with age. Some (particularly in younger patients) may be associated with familial
syndromes such as neuro® bromatosis and Li-Fraumeni syndrome. They usually present as a painless mass. Features of a soft
tissue lump suggestive of malignancy are:
· size . 5 cm diameter
· enlarging
· painful
· deep to fascia
· solid mass (not cystic)
· recurrence at site of previous excision (whatever the previous histology)
Any such lesions should immediately be referred to a specialist sarcoma service.
Investigations
The biopsy should ideally be undertaken by the specialist surgeon who will be responsible for the de® nitive operation because
the biopsy tract will need to be resected at that procedure. An excision biopsy or `shell-out’ is never appropriate because
sarcomas typically form a pseudocapsule that is not a barrier to spread. The increasing use of cytogenetic analysis in diagnosis
and monitoring of treatment requires fresh tissue from the initial biopsy.
When a sarcoma is suspected or demonstrated, staging investigations should be performed by the specialistteam before biopsy,
because haematoma, oedema and scar tissue reduce the yield of diagnostic information and delineation of the tumour extent,
particularly in relation to neurovascular structures. Films of suspected sarcomas should be reviewed by Radiologists trained
and experienced in this work. The following are required before biopsy to de® ne the primary tumour:
· high de® nition plain radiographs in two planes
· C.T. or preferably M.R.I scan of the tumour
The following are required before de® nitive surgery to exclude metastases:
· CXR and C.T scan of thorax
· bone scan (for primary bone tumours)
· FBC, U 1 E, LFT, LDH
· in selected cases, bone marrow biopsy
Close co-operation is required between the radiologists, surgeon, pathologist and oncologists. Sarcomas are not only a
heterogeneous group of tumours but a wide range of appearances can occur within individual tumours. Special training and
membership of national bone or soft tissue sarcoma pathology panels is required to gain experience in the interpretation of
these rare tumours.In orderto be ableto comment on grade,necrosis,mitoticrate and adequacy of the margins,the pathologist
mustbe able to orientate the specimen accurately before tissue retraction occurs. Trojani grading should be used for soft tissue
sarcomas. Pathology review by a sarcoma panel is obligatory for entry into clinical trials and leads to revision of the diagnosis
in 10± 30% of cases.196 Letters to the Editor
De® nitive Surgery
Surgery for primary bone tumours and most soft tissue sarcomas should only be undertaken by appropriately trained surgical
oncologists.This will usually imply an orthopaedic oncologist for bone tumours or a surgeon working in a recognised sarcoma
unit with appropriate training and experience.It is essential they work within a multidisciplinary team with appropriate support
facilities. There is no place for the ª occasional operatorº for these tumours.
Surgery is de® ned as:-
IncompleteÐ when any macroscopic tumour is left in situ. This requires re-excision.
MarginalÐ when the pseudocapsule is visible or any clearance margin is , 1 cm without fascia
Wide - when there is a cuff of normal tissue at least 1 cm laterally (or a fascial plane) and 3 cm longitudinally
RadicalÐ when the entire muscular compartment
ContaminatedÐ when rupture of the pseudocapsule results in tumour spillage
Adjuvant Treatment
For primary bone tumours, pre and post operative chemotherapy should be given in accordance with the current MRC/EOI
protocols. Referral to a regional oncology unit is essential for this.
For soft tissue sarcomas, the role of adjuvant chemotherapy is uncertain. Patients with high grade tumours should be
considered for enrolment into the current EORTC soft tissue sarcoma study. This requires an early decision regarding
chemotherapy and all cases should be discussed at a multidisciplinary meeting following de® nitive histology of the resected
tumour.Adjuvant radiotherapy is required for mostsoft tissuesarcomas and closelinksbetween theoperating surgeon,surgical
unit and the local radiotherapist are essential.
Follow up and Recurrence
Patients can present with local recurrence of any sarcoma many years after primary surgery. They should be promptly referred
back to the specialist sarcoma team for consideration of de® nitive surgery.
Some patients will have metastases at presentation and many others will develop them at a later date. Some of these,
particularly pulmonary metastases, can be treated by surgery. For this reason, sarcoma patients should be followed up by the
specialist sarcoma team, with regular CXRs. Widespread metastases are incurable, but can be palliated by chemotherapy in
a proportion of case. Treatment should be given by a medical oncologist in the specialist team using current protocols of the
MRC and EORTC groups.
PROMPT REFERRAL OF ANY SUSPECTED MUSCULOSKELETAL MALIGNANCY TO A REGIONAL/
SUPRAREGIONAL CENTRE IS STRONGLY RECOMMENDED.